CLOs on the Move

Radian Generation

www.radiangen.com

 
Radian Generation is meeting you where you are with adaptive solutions for each stage of the project lifecycle to help manage assets, ensure compliance, and scale investments for renewable facilities and their portfolios. Our Solutions: Asset Management Services, Compliance & Security Services, Software Solutions.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Scott Rice

Scott Rice is a Broken Arrow, OK-based company in the Business Services sector.

District of Columbia Public Schools (DCPS)

DCG is a District of Columbia-based digital platform that publishes information about executive, legislative, judicial, and employment programs.

Stewart'S Mobile Concepts

Stewart'S Mobile Concepts is a Huntington Station, NY-based company in the Business Services sector.

Cesar Chavez Academy High Schl

Cesar Chavez Academy High Schl is a Detroit, MI-based company in the Business Services sector.

enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN